Trial Profile
Pharmacodynamic Evaluation of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jul 2021
Price :
$35
*
At a glance
- Drugs Clopidogrel (Primary) ; Ticagrelor
- Indications Coronary artery disease
- Focus Pharmacodynamics
- Acronyms SWAP-4
- 17 May 2021 Results presented at the 70th Annual Scientific Session of the American College of Cardiology
- 15 Mar 2018 Status changed from active, no longer recruiting to completed.
- 11 Mar 2018 Primary endpoint (Platelet reactivity Unit-superiority of C-600 mg-24h versus C-75 mg-24h after switching from ticagrelor on PRU levels) has not been met, according to results published in the Circulation Journal.